Corticosteroids in the management of acute multiple sclerosis exacerbations
Author(s) -
Ide Smets,
Laura Van Deun,
Cedric Bohyn,
Vincent Van Pesch,
Ludo Vanopdenbosch,
Dominique Dive,
Véronique Bissay,
Bénédicte Dubois
Publication year - 2017
Publication title -
acta neurologica belgica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.474
H-Index - 34
eISSN - 2240-2993
pISSN - 0300-9009
DOI - 10.1007/s13760-017-0772-0
Subject(s) - medicine , multiple sclerosis , regimen , adverse effect , relapsing remitting , disease , neurology , intensive care medicine , pregnancy , disease management , pediatrics , fingolimod , immunology , psychiatry , biology , genetics , parkinson's disease
Multiple sclerosis (MS) is an autoimmune, inflammatory demyelinating disease of the central nervous system characterized in the majority of the patients by a relapsing-remitting disease course. For decades high-dosage corticosteroids (CS) are considered the cornerstone in the management of acute MS relapses. However, many unanswered questions remain when it comes to the exact modalities of CS administration. In this review on behalf of the Belgian Study Group for MS we define the efficacy of CS in reducing MS-related morbidity and examine whether the effect is different according to type of CS, route of administration, cumulative dosage, timing of initiation and disease course. We also review the use of CS in combination with other MS treatments and during pregnancy and lactation. Furthermore, we delineate the relevant adverse events due to a pulse CS regimen and present a decision tree that can be used when treating MS relapses in clinical practice.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom